Interesting Research Topics in Pediatric Gastroenterology
Based on current gaps in evidence and emerging priorities, the most compelling research areas in pediatric gastroenterology center on implementation science, microbiome-guided therapy, non-invasive disease monitoring, and transition of care—all with direct impact on patient outcomes.
Implementation Science and Quality Improvement (T3 Translational Research)
The most critical research gap exists in understanding how to reliably implement evidence-based care across diverse practice settings. 1
Determining which specific quality improvement interventions (previsit planning, self-management support, population management) have the greatest impact on clinical outcomes remains understudied, despite demonstrated improvements in remission rates from 55% to 68% in Crohn's disease through systematic QI approaches 1
Understanding contextual factors that determine implementation success—including senior leadership support, institutional QI culture, financial models, and team dynamics—requires rigorous investigation, as these factors explain why some centers achieve >85% remission rates while others show minimal improvement 1
Developing methods to rapidly identify and implement new treatment recommendations as they emerge from clinical trials represents a critical need, as current evidence shows only 60% of recommended care is actually delivered to patients 1
Studying how to minimize unintended variation in care is essential, given that immunomodulator use at diagnosis varies from 30% to nearly 100% across centers without clear clinical justification 1
Microbiome Research with Clinical Application
Microbiome profiling for diagnosis, phenotyping, and treatment individualization represents a high-yield research frontier with immediate clinical relevance. 2, 3
Developing and validating diagnostic indexes based on bacterial abundance shows promise, with patients having high diagnostic indexes demonstrating 2.5 times higher odds of having IBD 2
Creating prognostic indexes to predict need for biologic therapy is particularly valuable, as patients with high prognostic indexes have 2.1 times higher odds of requiring biologics, and those with severe dysbiosis show associations with extensive disease, surgery, and non-mucosal healing 2, 3
Investigating microbiome-based phenotyping to distinguish Crohn's disease from ulcerative colitis, as CD patients show lower Bifidobacterium abundance and patients needing biologics have lower butyrate-producing bacteria 2, 3
Understanding why dysbiosis persists after therapy regardless of treatment type or mucosal healing achievement requires mechanistic investigation 3
Exploring the gut-brain axis and microbiome's role in conditions like autism, irritable bowel syndrome, and the broader impact on neurodevelopment 4, 5
Non-Invasive Disease Monitoring
Intestinal ultrasound implementation and validation in pediatric populations represents an urgent research priority given its rapid adoption and potential to transform IBD monitoring. 6
Establishing pediatric-specific protocols, normal values, and training standards for intestinal ultrasound is critical as this modality gains acceptance 6
Validating ultrasound findings against clinical outcomes (hospitalization, surgery, quality of life) rather than just endoscopic correlation is needed 6
Determining optimal monitoring intervals and treatment adjustment algorithms based on ultrasound findings requires prospective study 6
Comparing cost-effectiveness and patient preference between ultrasound, biomarkers, and endoscopy for disease monitoring 6
Transition of Care Research
The transition from pediatric to adult care represents a vulnerable period with minimal evidence guiding best practices, despite 20% of CD and 12% of UC presenting before age 20. 7
Validating transition readiness assessment tools using meaningful outcomes (disease control, healthcare utilization, adherence, quality of life, continuity of care) rather than just readiness scores 7
Studying optimal transition planning strategies, including patient education methods and gradual responsibility shifts, as no studies currently address best practices 7
Conducting longitudinal US-based studies tracking patients through transition completion, as existing studies are primarily European with mixed results 7
Developing and testing transition policies that can be systematically implemented and monitored across institutions 7
Treatment Optimization Studies
Several specific therapeutic questions require investigation to optimize outcomes while minimizing toxicity. 8, 9, 10
Comparative effectiveness of exclusive enteral nutrition versus biologics as first-line therapy in pediatric Crohn's disease, given EEN's effectiveness but compliance challenges 9, 10
Optimal timing and sequencing of biologic agents (anti-TNF, vedolizumab, ustekinumab) in pediatric populations, as most data extrapolates from adult studies 9, 10
Therapeutic drug monitoring strategies to optimize thiopurine dosing, as only 69% of patients with normal TPMT receive recommended doses 1
Mucosal healing as a treatment target and its impact on long-term outcomes including growth, bone health, and disease complications in children 8, 9
De-escalation strategies for patients achieving sustained remission, balancing relapse risk against long-term medication exposure 9
Disease-Specific Emerging Areas
Beyond IBD, several pediatric GI conditions require focused research attention. 11, 12
Pediatric non-alcoholic fatty liver disease (NAFLD) pathophysiology, role of nutrition as therapeutic target, and evidence for specific interventional strategies including vitamin E, probiotics, and omega-3 fatty acids 11
Gastroesophageal reflux disease diagnostic accuracy studies and RCTs for therapeutic interventions, as current guidelines acknowledge significant evidence gaps 12
Nutritional management in neurological impairment, including optimal assessment methods, feeding modalities, and intervention timing 11
Metabolic disorders requiring dietary management, with focus on generating higher-quality evidence beyond expert consensus 11